Anika Gupta

Anika Gupta

Principal atGVCambridge, MA

Anika Gupta Vatsa is a principal at GV focusing on biotech investments. She represents GV on boards and previously worked at Foundation Medicine and Merck.

What Anika can write

Writes checks of$10M to $30M+
Comes in atSeed, Series A, Series BCan lead the round
Ownership target7-10%At first check
Best routeA warm introAsk a founder in their portfolio.

GV writes $10M to $30M+ checks, larger than 97% of firms in the atlas.

Bars: how many firms report each check band. Highlighted: GV.

Career

  1. Foundation Medicine
  2. Merck
  3. GV · Principal
    Now
  4. Foundation Medicine · bioinformatics frameworks for patient stratification
  5. Merck · immunotherapy response prediction

Companies founded

MIT Biotech Group

Investments named in public bios

EpiBiologicsPretzel Therapeutics

Focus

life sciencesgrowthbiotechseedearly stage

Education

Harvard University and the Broad Institute of MIT and Harvard, Ph.D. in bioinformatics and genomicsMIT, B.S. in Computer Science and Molecular BiologyHarvard University, Ph.D. in bioinformatics and genomics

Also at GV

Partners like Anika

At firms with a similar stage, sector and check size.

Alert me when GV is active

One email when Anika's firm raises a fund, adds a partner or shows new activity.

Founders and investors at a Mode VC gathering

Send Mode VC your deck

Raising a pre-seed or seed round? We write $1M to $5M first checks and help founders with distribution. A partner reads every deck.

Send your deck

Questions

Who is Anika Gupta?

Anika Gupta Vatsa is a principal at GV focusing on biotech investments. She represents GV on boards and previously worked at Foundation Medicine and Merck.

How much does Anika Gupta invest?

Anika Gupta invests through GV, which writes checks of $10M to $30M+ at seed, series a, series b.

How do I pitch Anika Gupta?

A warm intro from a founder GV backed works best.

What did Anika Gupta do before GV?

Foundation Medicine; Merck; bioinformatics frameworks for patient stratification at Foundation Medicine; immunotherapy response prediction at Merck.

Last updated 2026-10-15. Is this you? Ask for a correction.